Turagam Mohit K, Downey Francis X, Kress David C, Sra Jasbir, Tajik A Jamil, Jahangir Arshad
University of Missouri-Columbia School of Medicine, One Hospital Drive, Columbia, MO 65212, USA.
Expert Rev Clin Pharmacol. 2015 Mar;8(2):233-50. doi: 10.1586/17512433.2015.1018182.
Atrial fibrillation (AF) complicating cardiac surgery continues to be a major problem that increases the postoperative risk of stroke, myocardial infarction, heart failure and costs and can affect long-term survival. The incidence of AF after surgery has not significantly changed over the last two decades, despite improvement in medical and surgical techniques. The mechanism and pathophysiology underlying postoperative AF (PoAF) is incompletely understood and results from a combination of acute and chronic factors, superimposed on an underlying abnormal atrial substrate with increased interstitial fibrosis. Several anti-arrhythmic and non-anti-arrhythmic medications have been used for the prevention of PoAF, but the effectiveness of these strategies has been limited due to a poor understanding of the basis for the increased susceptibility of the atria to AF in the postoperative setting. In this review, we summarize the pathophysiology underlying the development of PoAF and evidence behind pharmacological approaches used for its prevention in the postoperative setting.
心房颤动(AF)合并心脏手术仍然是一个主要问题,它会增加术后中风、心肌梗死、心力衰竭的风险以及成本,并可能影响长期生存。尽管医疗和手术技术有所改进,但在过去二十年中,术后AF的发生率并未显著变化。术后AF(PoAF)的机制和病理生理学尚未完全明确,它是由急性和慢性因素共同作用导致的,这些因素叠加在具有间质纤维化增加的潜在异常心房基质上。几种抗心律失常和非抗心律失常药物已被用于预防PoAF,但由于对术后心房对AF易感性增加的基础了解不足,这些策略的有效性有限。在本综述中,我们总结了PoAF发生发展的病理生理学以及术后用于预防PoAF的药理学方法背后的证据。